Correction updates affiliations in indirubin-IBRV study

A correction has been published for the paper, “Exploration of the effect and mechanism of indirubin on infectious bovine rhinotracheitis virus based on network pharmacology,” a February 4, 2026 research article in BMC Veterinary Research. Based on the available indexing and article records, the change concerns author affiliation details, not the paper’s core data or conclusions. The corrected affiliations connect the authors to Xinjiang Agricultural University, the Xinjiang Key Laboratory of New Drug Research and Development for Herbivores, and the Xinjiang Academy of Animal Sciences. (pubmed.ncbi.nlm.nih.gov)

That distinction matters because the original paper is part of a broader effort to identify new antiviral approaches for infectious bovine rhinotracheitis, or IBR. IBR is caused by bovine alphaherpesvirus 1 and remains a consequential cattle disease because it can drive respiratory signs, reproductive disease, immunosuppression, and downstream production losses. Reviews and diagnostic papers continue to describe the disease as highly contagious and economically important, while current control still leans heavily on prevention, surveillance, and supportive management rather than novel therapeutics. (bmcvetres.biomedcentral.com)

In the original study, the researchers combined network pharmacology with wet-lab validation in Madin-Darby bovine kidney, or MDBK, cells. They reported screening 81 potential indirubin targets related to IBR, identifying mitochondrial-associated targets through GO analysis, and mapping multiple pathways through KEGG analysis. Experimentally, they found that indirubin inhibited IBRV replication in MDBK cells and reduced two markers associated with mitochondrial injury during infection: elevated reactive oxygen species and mitochondrial membrane potential depolarization. The authors concluded that indirubin may have anti-IBRV activity by regulating ROS production and inhibiting mitochondrial dysfunction. (bmcvetres.biomedcentral.com)

The paper also builds directly on the group’s earlier line of work around IBRV-induced mitochondrial damage. In the article’s background section, the authors say prior research from their team showed that IBRV infection in MDBK cells causes mitochondrial injury, including increased ROS and reduced mitochondrial membrane potential. That framing helps explain why indirubin was selected: the compound has been studied for anti-inflammatory, antiviral, and mitochondria-related effects in other settings, making it a plausible exploratory candidate for a mechanistic IBRV study. (bmcvetres.biomedcentral.com)

I didn’t find substantial outside expert commentary on the correction itself, which is not unusual for affiliation-only updates. I also didn’t find evidence in the accessible records that the journal has altered the study’s results, methods, or interpretation. The available PubMed and Springer records still describe the same main findings and list the article as open access research published in 2026. That suggests the correction is best understood as a bibliographic and attribution fix, not a scientific reversal. This is an inference based on the records reviewed, because the standalone correction notice was not surfaced in the accessible search results. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, especially those tracking cattle health, pharmacology, and translational virology, the practical takeaway is twofold. First, corrections to affiliations may seem minor, but they matter for transparency, institutional credit, and accurate citation trails. Second, the underlying science remains early-stage. The indirubin work is interesting because it links antiviral activity with mitochondrial protection, a mechanism that could eventually inform new therapeutic strategies for IBRV. But this is still cell-culture research, not a field study, not a clinical trial, and not a product announcement. It should be read as hypothesis-generating rather than practice-changing. (bmcvetres.biomedcentral.com)

That caution is especially important in the IBR space, where prevention has historically moved faster than treatment innovation. Recent literature continues to focus on diagnostics, surveillance, pathogenesis, and vaccination, including work on rapid detection assays, molecular epidemiology, and marker vaccines. Against that backdrop, a compound like indirubin may attract attention as a research lead, but it still faces the usual translational hurdles around dosing, safety, delivery, efficacy in live animals, and regulatory development. (pubmed.ncbi.nlm.nih.gov)

What to watch: The next meaningful milestone would be a clearly indexed standalone correction notice, followed by in vivo validation or larger translational studies that test whether indirubin’s anti-IBRV and mitochondria-protective effects can be reproduced in animals, not just in MDBK cells. (pubmed.ncbi.nlm.nih.gov)